Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2026-10-21 DOI:10.1080/17512433.2026.2749579

Xiaomin Wang, Liyan Dong, Guo Lin, Zhixin Jiang, Yue Hou, Wenxiu Zhang, Ying Ma, Yongguo Zhang, Jiang Chen, Xingshun Qi

{"title":"Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study.","authors":"Xiaomin Wang, Liyan Dong, Guo Lin, Zhixin Jiang, Yue Hou, Wenxiu Zhang, Ying Ma, Yongguo Zhang, Jiang Chen, Xingshun Qi","doi":"10.1080/17512433.2026.2749579","DOIUrl":null,"url":null,"abstract":"Background: Increasing antibiotic resistance has undermined Helicobacter pylori eradication. Despite a low resistance to minocycline, clinical evidence for minocycline-containing bismuth quadruple therapy (MCQT) is limited. This retrospective study aimed to evaluate its clinical efficacy.Research design and methods: Patients who had Helicobacter pylori infection by 13C-urea breath testing at our department from October 2024 to July 2025 were screened. They were classified into MCQT (minocycline-amoxicillin-acid-inhibitors-bismuth [MAAB], minocycline-clarithromycin-acid-inhibitors-bismuth [MCAB], and minocycline-levofloxacin-acid-inhibitors-bismuth [MLAB]) and non-MCQT (amoxicillin-clarithromycin-acid-inhibitors-bismuth [ACAB] and amoxicillin-levofloxacin-acid-inhibitors-bismuth [ALAB]). Four comparisons (MAAB vs. ACAB, MCAB vs. ACAB, MLAB vs. ALAB, and MAAB vs. ALAB) were separately performed in treatment‑naïve and treatment‑experienced patients. Logistic regression analyses were used to identify the influencing factors.Results: Overall, 687 treatment-naïve and 92 treatment-experienced Helicobacter pylori patients were included. MAAB demonstrated significantly higher eradication rates than ACAB in both groups (p = 0.020, p = 0.016), with no significant differences in other comparisons. Multivariate logistic regression analysis indicated that female was independently associated with a higher eradication rate in treatment-naïve patients in three comparisons (MAAB vs. ACAB, p = 0.021; MCAB vs. ACAB, p = 0.009; MAAB vs. ALAB, p = 0.043).Conclusions: MCQT achieves favorable Helicobacter pylori eradication rates in both treatment-naïve and treatment-experienced patients, and MAAB demonstrates a significantly higher eradication rate than ACAB.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6000,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2026.2749579","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Increasing antibiotic resistance has undermined Helicobacter pylori eradication. Despite a low resistance to minocycline, clinical evidence for minocycline-containing bismuth quadruple therapy (MCQT) is limited. This retrospective study aimed to evaluate its clinical efficacy.

Research design and methods: Patients who had Helicobacter pylori infection by ¹³C-urea breath testing at our department from October 2024 to July 2025 were screened. They were classified into MCQT (minocycline-amoxicillin-acid-inhibitors-bismuth [MAAB], minocycline-clarithromycin-acid-inhibitors-bismuth [MCAB], and minocycline-levofloxacin-acid-inhibitors-bismuth [MLAB]) and non-MCQT (amoxicillin-clarithromycin-acid-inhibitors-bismuth [ACAB] and amoxicillin-levofloxacin-acid-inhibitors-bismuth [ALAB]). Four comparisons (MAAB vs. ACAB, MCAB vs. ACAB, MLAB vs. ALAB, and MAAB vs. ALAB) were separately performed in treatment‑naïve and treatment‑experienced patients. Logistic regression analyses were used to identify the influencing factors.

Results: Overall, 687 treatment-naïve and 92 treatment-experienced Helicobacter pylori patients were included. MAAB demonstrated significantly higher eradication rates than ACAB in both groups (p = 0.020, p = 0.016), with no significant differences in other comparisons. Multivariate logistic regression analysis indicated that female was independently associated with a higher eradication rate in treatment-naïve patients in three comparisons (MAAB vs. ACAB, p = 0.021; MCAB vs. ACAB, p = 0.009; MAAB vs. ALAB, p = 0.043).

Conclusions: MCQT achieves favorable Helicobacter pylori eradication rates in both treatment-naïve and treatment-experienced patients, and MAAB demonstrates a significantly higher eradication rate than ACAB.

查看原文本刊更多论文

含米诺环素铋四联疗法治疗幽门螺杆菌感染的疗效：一项单中心回顾性研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.